Meghan Berkenstock - research works

At diagnosis, 31/52 patients (59.6%) had unilateral disease.

During follow-up, 11 developed fellow-eye involvement (0.08/person-year; 95% CI 0.04 to 0.13), with the highest incidence within 5 years of diagnosis (0.20/person-year; 95% CI 0.09 to 0.36).

At diagnosis, CNV was present in 34/73 eyes (46.6%).

During follow-up, 20 eyes developed incident CNV (0.06/eye-year; 95% CI 0.04 to 0.10), highest within 5 years of diagnosis (0.14/eye-year; 95% CI 0.08 to 0.22).

Of 97,616,995 patients in the database, 205,193 (0.24%) were diagnosed with uveitis and 29,270 with scleritis (0.029%).

The cumulative incidences of depression, anxiety, and SI were 3,927; 4,936; and 457 per 100,000 patients with uveitis and 3,792; 5,064; and 357 per 100,000 patients with scleritis, respectively.

The highest subgroup risks appeared in uveitis with glaucoma and depression (1.59, 1.55-1.62, p < 0.05) and scleritis with glaucoma and depression (1.47, 1.37-1.60, p < 0.05).

Risk ratios also showed a decreased risk of depression and anxiety in uveitis patients compared to patients with type 2 diabetes mellitus and rheumatoid arthritis.

Compared to nonsmokers, the OR for developing uveitis was 1.459 times higher for cannabis users ( P = 0.016, 95% confidence interval [CI]: 1.072-1.985) and 1.712 times higher for those exposed to tobacco smoke ( P < 0.001, 95% CI: 1.366-2.146).

The odds of developing oMMP were 1.923 times higher for cigarette users ( P = 0.042, 95% CI: 1.011-3.657).

The odds of developing glaucoma were 1.551 times higher for cigarette users ( P < 0.001, 95% CI: 1.234-1.95), 1.547 times higher for vape users ( P < 0.002, 95% CI: 1.223-1.956), 1.574 times higher for chewing tobacco users ( P < 0.001, 95% CI: 1.25-1.982), and 1.707 times higher for those exposed to tobacco smoke ( P = 0.001, 95% CI: 1.229-2.37).

Among 152,281,229 patients in the TriNetX network, 175 were identified as probable PVRL cases.

The mean age at diagnosis was 59.4 years (standard deviation: 15.6; range: 19-90), and 59.52% were Caucasian.

Postdiagnosis comorbidities included glaucoma (15.0%), cystoid macular edema (13.6%), and low vision (13.2%).